| External factors: | Hecogenin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Lung cancer |
| Experiment: | Flow cytometry//SA-β-gal activity assay |
| Description: | At 50 μM, there was a small decrease in cells at S phase and a small increase in cells at G0/G1 and G2/M . This effect was enhanced with increased concentrations of hecogenin acetate. At 75 μM, 74% of cells were induced to cell cycle arrest in G0/G1 while 84.3 % of cells were induced to G0/G1 cell cycle arrest by hecogenin acetate 100 μM;Control cells showed only few SA-β-Gal staining spots, in contrast to cells treated with hecogenin acetate 50 μM where clusters of senescent cells were evident. |
| Target gene: | ERK1/2//MMP2 |
| R-EF-Target gene: | --//-- |
| Official symbol(s): | ERK1/2//MMP2 |
| Target gene experiment: | Western blot |
| Target gene description: | Hecogenin acetate completely abolished ERK 1/2 phosphorylation induced by H2O2.Hecogenin acetate was able to inhibit the increase in MMP-2 content caused by H2O2 treatment. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: